Altimmune, Inc.
Records under this name other than the patents Altimmune, Inc. holds now: patents now held by others, patents whose terms have ended, and its applications, pending or abandoned. None of them is counted in the 3 patents it holds.
Showing 1 to 9 of 9 · Back to Altimmune, Inc.
| Patent | Title | Status | Expires | Confidence |
|---|---|---|---|---|
| US 11,395,802 | Biodegradable Polymeric Particles Encapsulating an Active Agent, Pharmaceutical Compositions and Uses Thereof Formerly held In force · High confidence | In force | High confidence | |
| US 11,382,968 | Coronavirus Immunogenic Compositions and Uses Thereof Lapsed on the fee record Ended Jul 12, 2026 · High confidence | Lapsed on the fee record | Ended Jul 12, 2026 | High confidence |
| US 9,855,328 | Immunization of avians by administration of non-replicating vectored vaccines Lapsed on the fee record Ended Jan 2, 2026 · Medium confidence | Lapsed on the fee record | Ended Jan 2, 2026 | Medium confidence |
| US 11,141,477 | Rapid and prolonged immunologic-therapeutic Lapsed on the fee record Ended Oct 12, 2025 · From the USPTO record | Lapsed on the fee record | Ended Oct 12, 2025 | From the USPTO record |
| US 11,040,099 | Rapid and prolonged immunologic therapeutic Lapsed on the fee record Ended Jun 22, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 22, 2025 | From the USPTO record |
| US 11,040,100 | Rapid and prolonged immunogic therapeutic Lapsed on the fee record Ended Jun 22, 2025 · From the USPTO record | Lapsed on the fee record | Ended Jun 22, 2025 | From the USPTO record |
| US 9,605,275 | Rapid and prolonged immunologic-therapeutic Lapsed on the fee record Ended Mar 28, 2025 · From the USPTO record | Lapsed on the fee record | Ended Mar 28, 2025 | From the USPTO record |
| US 10,744,195 | Immunization of Avians by Administration of Non-Replicating Vectored Vaccines Lapsed on the fee record Ended Aug 18, 2024 · Low confidence | Lapsed on the fee record | Ended Aug 18, 2024 | Low confidence |
| US 9,968,667 | Targets and compositions for use in decontamination, immunoprophylaxis, and post-exposure therapy against anthrax Term ended Term ended Jul 12, 2024 · From the USPTO record | Term ended | Term ended Jul 12, 2024 | From the USPTO record |